We are developing a breakthrough oral drug (at pre-IND stage) to treat diabetic retinopathy and other retinal and neuro-degenerative diseases by targeting disequilibrium in fatty acid metabolism that leads to neuroinflammation and degenerative cell disease.
Address
CaliforniaUnited States